Ranvet’s PERGOLIDE Aids in the therapy of Equine Cushing’s Syndrome SCHEDULED PRODUCT VET ONLY Potent oral treatment for horses with confirmed Equine Cushing’s Syndrome ACTIVE CONSTITUENTS Pergolide Mesylate 1mg/5mL Features Benefits Pergolide mesylate acts as an ergot dopamine Significantly improve the quality of life for receptor agonist at both D1 and D2 receptor horses suffering from ECS. sites in the brain that control the production of dopamine within the hypothalamus. Once daily oral liquid dosage. Controls adrenal secretions of glucocorticoid Reduces clinical signs associated with ECS. hormones characteristic of ECS. Product is registered by the APVMA for the treatment of ECS. Supported by an extensive clinical trial program. DIRECTIONS FOR USE/CONTRAINDICATIONS Administer orally over the tongue once daily. Consult your veterinarian before altering the dosage. If the dosage is to be increased it is recommended that 0.5mg increments be assessed before higher daily doses are employed. IMPORTANT NOTE: ECS is a disease which is managed, not cured and therefore lifelong treatment is required for affected horses. For best results pharmaceutical therapy should be employed in adjunct with nutritional strategies. Retraction of Ranvet’s Pergolide therapy will cause re-establishment of clinical signs within 7-10 days. DOSAGE RATES 5mL/500kg bodyweight (0.002mg/kg bodyweight) once daily. Each 5mL dose provides 1mg pergolide mesylate. The daily dose may be gradually increased as directed by a veterinarian if clinical improvement fails to occur after one to two months of therapy. PACK SIZE(S) 200mL Ranvet Pty Ltd 10-12 Green Street, Banksmeadow NSW 2019 Australia Ph: 612 9666 1744 . Fax: 612 9666 1755 Web: www.ranvet.com.au . Email: [email protected].